FLT1 - fms related receptor tyrosine kinase 1 Gene

Canis lupus familiaris (sub-species: familiaris)

Also known as VEGFR-1

Gene ID: 403727 | Gene type: protein coding

About FLT1

Primary_assembly 25: 11,360,101-11,538,419 forward strand.ROS_Cfam_1.0:CM025124.1

This gene has 4 transcripts (splice variants), 199 orthologues and 54 paralogues.

mRNA	Protein	Name
XM_038434969.1	XP_038290897.1	vascular endothelial growth factor receptor 1 isoform X4
XM_038434966.1	XP_038290894.1	vascular endothelial growth factor receptor 1 isoform X2
XM_038434965.1	XP_038290893.1	vascular endothelial growth factor receptor 1 isoform X1
XM_038434968.1	XP_038290896.1	vascular endothelial growth factor receptor 1 isoform X4
XM_038434967.1	XP_038290895.1	vascular endothelial growth factor receptor 1 isoform X3
XM_038434966.1	XP_038290894.1	vascular endothelial growth factor receptor 1 isoform X2
XM_038434965.1	XP_038290893.1	vascular endothelial growth factor receptor 1 isoform X1
XM_038434968.1	XP_038290896.1	vascular endothelial growth factor receptor 1 isoform X4
XM_038434969.1	XP_038290897.1	vascular endothelial growth factor receptor 1 isoform X4
XM_038434967.1	XP_038290895.1	vascular endothelial growth factor receptor 1 isoform X3

IG_like

Ig_3

IG_like

I-set

PKc_like

Protein Preferred Names

Protein Names

vascular endothelial growth factor receptor 1

ascular endothelial growth factor/vascular permeability factor receptor	fms related tyrosine kinase 1
fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)

Clinical Phase

Bioactive Molecules (8)

Cat. No.	Product Name	Effect	Purity	Phase
HY-50751	Linifanib		99.39%	Phase 3
HY-10205	Cediranib		99.87%	Phase 3
HY-10517	Orantinib		99.29%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-110272	Vatalanib succinate	Inhibitor	/	Phase 3
HY-50703	MK-2461	Inhibitor	99.28%	Phase 2
HY-10204	OSI-930		98.33%	Phase 1
HY-100315	XL 999	Inhibitor	99.01%	Phase 1

Inhibitory Antibodies (2)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99364	Icrucumab		99.9%	Phase 2
HY-P991430	RO5323441	Inhibitor	95.85%	Phase 1

Pre-clinical Phase

Bioactive Molecules (17)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-15813	FIIN-1	Inhibitor	99.04%	Unkown
HY-P10831	GNQWFI	Antagonist	99.45%	Unkown
HY-108551	MG-262		95.0%	Unkown
HY-P5438	Srctide	Substrate	99.71%	Unkown
HY-145293	TNIK-IN-3	Inhibitor	99.79%	Unkown
HY-101219	VEGFR-IN-1	Inhibitor	99.07%	Unkown
HY-50751G	Linifanib (GMP)	Inhibitor	/	Unkown
HY-123586	L-783277	Inhibitor	/	Unkown
HY-168114	Multi-kinase inhibitor 3	Inhibitor	/	Unkown
HY-168115	Multi-kinase inhibitor 4	Inhibitor	/	Unkown
HY-181754	TPKI-39	Inhibitor	/	Unkown
HY-182354	VEGFR2-IN-84	Inhibitor	/	Unkown
HY-18692	Multi-kinase-IN-12	Inhibitor	/	Unkown
HY-RS04987	FLT1 Human Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS04988	Flt1 Mouse Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS04989	Flt1 Rat Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-174684	Human FLT1 mRNA		/	Unkown

Inhibitory Antibodies (1)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P990541	Anti-VEGFR1/FLT1 Antibody	Inhibitor	/	Unkown

Species	Symbol	Source	ID
Homo sapiens	FLT1	NCBI	NCBI:2321
Mus musculus	FLT1	NCBI	NCBI:14254
Rattus norvegicus	FLT1	NCBI	NCBI:54251

Name
Email *

	Sorry, but the email address you supplied was invalid.